Bristol-Myers joins forces with digital therapeutics co; Wearable cardioverter defibrillator scores $145M+ in Series C haul
→ Bristol-Myers Squibb has signed on digital therapeutics player Voluntis to develop a mobile app that will give cancer patients tips on managing their therapy and track symptoms. Paris-based Voluntis said the deal is part of its transition to focus on oncology while dropping direct commercialization plans for its diabetes business in favor of a partnering strategy.
→ A US company developing a wearable cardioverter defibrillator has just secured a mammoth $145.6 million in Series C financing. The round for Element Science was led by Deerfield Healthcare and Qiming Venture Partners USA and included the participation of investors Third Rock Ventures and Google Ventures. Their “Jewel patch” product rivals Zoll Medical’s LifeVest wearable, but Element contends its offering is more discreet and comfortable.
→ Months after Tissium — which is using technology originally developed in the prolific lab of MIT’s Bob Langer for its work on sealants — scored nearly $43 million in a Series B round, the Parisian medtech player has been awarded a €2.2 million grant to accelerate the development of its tissue adhesive in patients with chronic rhinosinusitis.